文献速递主动脉疾病

Cook Zenith Alpha腹主动脉内移植物行动脉瘤修复的中期结局

Midterm outcomes of aneurysm repair with the Cook Zenith Alpha abdominal endovascular graft.
PubMed 文献 · J Vasc Surg · 2022-03-31

这项单中心回顾性研究纳入2015年10月1日至2018年9月30日接受Zenith Alpha腹主动脉内移植物行EVAR的241例患者,65%在IFU外植入,4年免于再干预率66%,4年主动脉相关死亡免除率99%,肢体通畅不良是再干预主因。

要点

  • 241例接受Zenith Alpha EVAR,技术成功率99%,65%在IFU外植入。
  • 4年免于再干预率66%,免于主动脉相关死亡率99%。
  • 远端IFU外植入者1B型内漏显著更多(11例中10例,P=0.009)。

核心结论

  • Zenith Alpha行EVAR术后4年内主动脉相关死亡免除率可接受,多数患者在IFU外植入且该亚组1B型内漏显著更多,再干预主因为肢体通畅不良,其根本原因需进一步研究。

研究设计与样本

  • 回顾性单中心研究,纳入2015年10月1日至2018年9月30日接受Zenith Alpha腹主动脉内移植物治疗的全部患者241例,其中214例(89%)为无症状修复。

主要发现

  • 技术成功238例(99%),157例(65%)在IFU外植入,中位住院时间2天(四分位距2-3天),中位临床随访35.1个月(四分位距28.8-47.5个月)。
  • 4年Kaplan-Meier免于再干预率为66%(95%CI 59%-73%),再干预主因为髂支狭窄和闭塞(n=30;12%)及2型内漏(n=13;5%)。
  • 远端IFU外植入者发生1B型内漏显著更多(11例中10例,P=0.009)。
  • 术后1年观察到48例(25%)动脉瘤囊缩小,术后4年Kaplan-Meier主动脉相关死亡免除率为99%(95%CI 98%-100%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 肢体通畅不良的根本原因需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Outcome reports after endovascular aneurysm repair (EVAR) using the low-profile Zenith Alpha Abdominal Endovascular grafts (Cook Medical, Bjæverskov, Denmark) are sparse. We present results from a single-center cohort treated with the Zenith Alpha, from a period where the graft was the primary EVAR device choice. The aim of the study was to evaluate short- and midterm outcomes of patients treated with the Zenith Alpha. METHODS: A retrospective single-center study was performed including all patients treated with the Zenith Alpha graft from October 1, 2015 to September 30, 2018. All patients underwent computed tomography angiography (CTA) imaging preoperatively as well as at 3 and 12 months postoperatively. Hereafter, patients were followed yearly with duplex ultrasound and clinical exams. Additional imaging was performed on indication. All CTAs were analyzed using three-dimensional reconstruction software (Aquarius, TeraRecon, Durham, NC). Data was extracted from electronic charts according to a protocol that remained unchanged until the end of the study (December 31, 2020). The following outcomes were assessed according to Society for Vascular Surgery/International Society of Cardiovascular Surgeons reporting criteria: aortic-related and all-cause mortality, reinterventions, instruction for use (IFU) violations, endoleaks (ELs), and aneurysm shrinkage. RESULTS: A total of 241 patients were treated with the Zenith Alpha, and 214 (89%) were asymptomatic repairs. Technical success was achieved in 238 patients (99%). One hundred fifty-seven patients (65%) received implantation outside IFU. The median hospital length of stay was 2 days (interquartile range, 2-3 days). The median clinical follow-up was 35.1 months (interquartile range, 28.8-47.5 months). The 4-year Kaplan-Meier estimate of freedom from reintervention was 66% (95% confidence interval, 59%-73%). The main reasons for reinterventions were iliac limb stenosis and occlusion (n = 30; 12%) and type 2 EL (n = 13; 5%). Overall, significantly more patients with grafts implanted outside distal IFU developed type 1B ELs (n = 10/11; P = .009). Aneurysm sac shrinkage was observed in 48 patients (25%) 1 year postoperatively. The Kaplan-Meier estimate of freedom from aortic-related mortality was 99% (95% confidence interval, 98%-100%) 4 years postoperatively. CONCLUSIONS: EVAR with the Zenith Alpha shows acceptable freedom from aortic-related mortality up to 4 years postoperatively. The majority of patients were treated outside IFU, and significantly more type 1B ELs appeared in this subgroup of patients. The leading cause for reintervention was impaired limb patency. The root cause for impaired limb patency requires further investigation.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Broda M, Eiberg J, Vogt K, et al. Midterm outcomes of aneurysm repair with the Cook Zenith Alpha abdominal endovascular graft. J Vasc Surg. 2022. PMID: 35367569. doi:10.1016/j.jvs.2022.03.862

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。